The study team collected plasma from healthcare workers aged 21–48 years (mean 31) at 0, 28, and 180 days post-vaccination during the 2022–2023 influenza season. Investigators tested responses to the three vaccine viruses: A/H3N2, A/H1N1, and B/Victoria. Female responders began with higher anti-H3 IgG and greater antibody binding to FcγRIIB (CD32b) before vaccination. These pre-existing differences were not limited to a single timepoint; the cohort showed maintenance of these elevated levels through 180 days post-vaccination (DPV).
The authors reported these baseline differences rather than inferring causes. The source did not report mechanistic experiments to explain why females had greater pre-vaccination FcγRIIB-binding antibodies.
Data indicated that females had greater A/H3N2 neutralizing antibody (nAb) responses than males through 180 DPV. The difference was strain-specific: no analogous female advantage was observed for A/H1N1 or B/Victoria neutralization. The disparity was most pronounced among participants categorized as A/H3N2 responders, defined in the study by a ≥4-fold rise in nAb titers. The investigators emphasized that sex-specific differences in neutralization were persistent rather than transient, with females retaining higher H3N2 nAb at the 180-day timepoint.
The report did not provide vaccine dosing specifics or lot numbers in the abstract; those methodological details were not reported in the source summary provided here.
Memory B cells were isolated from responders and stimulated ex vivo with H3 antigen. The study team observed that memory B cells from female responders secreted more IgG than those from male responders at both 28 and 180 DPV. This finding tied enhanced neutralizing responses to a cellular correlate of humoral memory. Short-term secretion assays and the longitudinal sampling allowed the authors to compare both early and later memory outputs in parallel.
The source did not report additional phenotyping of B cell subsets or detailed assay conditions in the abstract; those methods may appear in the full manuscript or supplementary material.
Females had greater FcγRIIB (CD32b) antibody binding to H3 both before and after vaccination. Functional Fc-mediated assays also differed by sex. Female responders exhibited higher H3-specific antibody-dependent monocyte phagocytosis (ADMP) and stronger antibody-dependent natural killer cell (ADNK) responses, measured as IFNγ and CCL4 secretion. These functional readouts were elevated in females at baseline and remained higher following vaccination.
The investigators reported these Fc-mediated differences as potential contributors to the superior durability of humoral immunity in females. The report did not include causal experiments to prove that FcγRIIB binding directly causes improved durability; it instead presents correlative data from the cohort.
Among responders, ADMP positively correlated with sustained H3N2 neutralization through 180 DPV, but this relationship was observed in females only. The study team interpreted this sex-specific correlation as evidence that Fc-mediated, non-neutralizing functions may contribute to the durability of neutralizing antibody responses in females. The durability of ADMP, ADNK, and nAb collectively defined the observed sex differences in influenza vaccine–induced immunity in this cohort.
These correlations were derived from the timepoints and assays described; the source did not provide inferential statistics or p-values in the abstract text provided here.
Johns Hopkins Institutional Review Boards (IRB00091667) provided ethical approval for the work, and the dataset is protected under IRB restrictions. Individual-level clinical data are not publicly available; qualified Johns Hopkins researchers may apply for access through the IRB, and external collaborators may contact the corresponding author. Code is available on GitHub per the manuscript’s data/code statement.
This article is a medRxiv preprint and has not been peer reviewed. The authors proposed that higher pre-vaccination FcγR-binding antibodies in females might improve the durability of both neutralizing and non-neutralizing antibody responses, with possible relevance for next-generation influenza vaccines — a hypothesis that remains to be tested in controlled mechanistic studies or clinical trials. Open questions that the source notes include whether these sex-specific immune differences generalize across age groups, vaccine platforms, and different seasonal strains, and whether targeted vaccine design can leverage Fc-mediated functions to enhance durability. The report did not list specific regulatory milestones or ongoing trials; it instead presents cohort observations and suggests further investigation.